nuclear medicine News
-
US report endorses Australia’s use of low-enriched uranium for nuclear medicine production
Today, the United States (US) National Academies of Science released international recommendations to produce life-saving nuclear medicines using low enriched uranium (LEU) targets and eliminate high enriched uranium (HEU) use to help reduce world-wide proliferation risks. The recommendations endorse ANSTO’s use of LEU targets in nuclear medicine production and LEU fuel in its OPAL reactor. ...
-
Phase II study demonstrates prognostic value of uPAR-PET in head and neck cancer patients
Results from an investigator-initiated phase II study performed by researchers at Rigshospitalet and using the uTRACE[®] technology have now been published online ahead of print in the prestigious Journal of Nuclear Medicine. The abstract of the article is freely available here (https://pubmed.ncbi.nlm.nih.gov/34857658/). The phase II study The phase II trial (NCT02965001) aimed to ...
By Curasight
-
Christie Med Announces New Authorized Partner in Al Zahrawi for UAE Distribution of VeinViewer
As the leader in vein visualization technology throughout the world, Christie’s high-quality, made-in-the-USA, VeinViewer® Vision2 and VeinViewer® Flex, continue to provide customers with improved clinical outcomes such as increasing 1st stick success, decreasing medically not required PICC lines and enhancing patient satisfaction. We are committed to the continued growth of ...
-
Positron Corporation Retains FDA Consulting Firm in Preparation for 510K New Device Application
Niagara Falls, NY – February 17, 2022 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a nuclear medicine PET imaging device systems and clinical services company, is pleased to announce today that the Company has retained Medical Device Academy ”MDA”) as its consultant for the Company’s new PET/CT device 510K ...
-
Fine image, Intelligent service - IDC wonderful debut CMEF
The 77th China International Medical Equipment Fair (CMEF) was held at the National Convention and Exhibition Center in Shanghai from May 15-18, 2017. The exhibition space covered 220 000 sqm. Over 4000 representatives from 28 countries gathered at the CMEF, attracting 400 000 visitors and buyers annually. As a historically listed company in North America, IDC captures the Chinese market with an ...
-
FAPI featured in accolades at annual Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting
Congratulations to investigators at Hannover School of Medicine and Heidelberg University Hospital for receiving the 2022 SNMMI Image of the Year Award and JNM Editors’ Choice Award for Overall Best Article in 2021, respectively. Both use FAPI as the primary indicator and further underscore its potential impact as a novel radiopharmaceutical. Each year, SNMMI chooses an image that best ...
By SOFIE
-
BetaGlue Technologies announces new Board of Directors
BetaGlue (www.betaglue.com), an innovative Italian company in the field of interventional oncology today announced the appointment of its new Board of Directors, composed by investors representatives, independent industry experts and company CEO. New members of the board are Riccardo Palmisano, Company’s Chairman and Geoffroy De Ribains, as independent Board member. Antonino ...
-
Betaglue takes radiotherapy inside solid tumours: first patient treated
The first clinical results have shown that BAT-90 innovative radiotherapy platform makes it possible to treat only the area where the tumour is located, while avoiding the surrounding tissues, so as to combine treatment efficacy and patient safety CEO/CMO, Dr. Antonino Amato, said: "The confirmation in this first patient of the previous findings from the pre-clinical studies with BAT-90 opens ...
-
ABK Biomedical partners with the CNIC to enhance patient care
ABK Biomedical, which is developing a transformative Eye90 microspheres® technology, with the potential to provide in-procedure prognostic dosimetry for cutting-edge treatment of liver tumours – has partnered with the Canadian Nuclear Isotope Council. The CNIC is an independent body made up of representatives from the Canadian health sector, nuclear industry and leading research ...
-
The desperate need for medical isotopes
With preparations underway for manufacturing the MIFTEC Z-pinch (ZEBRA) Fusion Medical Isotope Generators, US Nuclear Corp. (OTCBB: UCLE) is one step closer to ending the dire worldwide shortage of medical isotopes. The federal government is so desperate to find a domestic, stable supply of medical isotopes that they recently awarded over $60 million in funding to 8 projects/companies working ...
-
A Message from Spectrum Dynamics Medical: Update to COVID-19
Healthcare providers managing patients during the COVID-19 pandemic are confronting new and unique operational and business challenges. During this time, our focus is on supporting you and the safety and well-being of our employees. We know our sales and technical support teams are vitally important to support you, as well as the communities where we serve. Many of you continue to provide nuclear ...
-
Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy
Lausanne, Switzerland- March 25, 2020 - Debiopharm, a Swiss-based biopharmaceutical company announced today having entered into a worldwide, exclusive license & research agreement with 3B Pharmaceuticals (3BP), a German biotechnology firm, to further the development of their radioligand program, now called Debio 0228, which targets the CAIX (Carbonic Anhydrase 9) enzyme to fight the ...
-
Cancer Targeted Technology Announces Advances with its PSMA-targeted PET Imaging and Radiotherapeutic Agents for Prostate Cancer at Upcoming Conferences
Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm, is focusing on small molecules that target pivotal enzyme targets on cancer. CTT’s theranostic program is focused on the development of two drugs, CTT1057 and CTT1403, that respectively diagnose and treat prostate cancer based on targeting the biomarker, Prostate Specific Membrane Antigen (PSMA). PSMA is ...
-
Betaglue technologies strengthen its expertise in strategic areas with four new managers
Betty Polikar, Gianluca De Danieli, Pietro Bubba Bello and Caia Bisaccioni strengthen the Clinical Research, Manufacturing and Quality areas Clinical developments continue on the advanced cancer radiotherapy platform, BAT-90, as the first breast cancer patient was treated Milan, October 19, 2022 - BetaGlue Technologies, a highly innovative company working in the Life Sciences sector, ...
-
Finally, Digital Myocardial Perfusion Imaging That’s Within Reach: SPECT CZT Technology Just Became More Accessible
Spectrum Dynamics Medical, Inc., announced today that they have a new offering into their industry-leading D-SPECT® family with the introduction of D-SPECT® VISTA. The new addition is specifically designed as an affordable entry into digital based solid-state Cadmium Zinc Telluride (CZT) myocardial perfusion imaging (MPI) for institutions wishing to transition from an older, analog ...
-
BetaGlue has enrolled the first patient treated with BAT-90 in its First-in-Human trials, taking radiotherapy inside solid tumours
The first clinicalfindingshave shown that BAT-90makes it possible to treat onlythe area where the tumour is located, while avoiding the surrounding tissues, so as to combine treatmentefficacy and patient safety BetaGlue Technologieshasenrolledthe first patientin a clinical trialwithBAT-90, the company’s cancer radiotherapy platform. The first clinical findings have shown thatBAT-90 ...
-
Theragenics to provide Sales and Marketing for C4 Imaging`s New Orion HDR MRI Markers
Theragenics Corporation, a medical device company serving the cancer treatment market, will provide sales and marketing for C4 Imaging’s novel, Orion Positive-Signal HDR MRI Lumen Marker. The marker is used prior to high dose rate (HDR) brachytherapy to accurately locate the position of the applicators that guide the placement of radioactive sources for the treatment of multiple cancers, ...
-
Cairn Diagnostics Delivers Virtual Administration of its Novel 13C-Spirulina Gastric Emptying Breath Test
Cairn Diagnostics, an innovative leader in providing cutting-edge breath tests intended for routine use in diagnostic medicine, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approval of the Company’s 13C-Spirulina Gastric Emptying Breath Test (GEBT) to now include “at home” administration under virtual supervision of Cairn Diagnostics. GEBT ...
-
ReShape Lifesciences Announces Stocking Order from Medical Supplier in Dubai
ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases announced today that it has received a significant order for its ReShape® Integrated Dual Balloon System from Al Zahrawi Medical a healthcare focused company specializing in medical, surgical, diagnostic and analytical lab and nuclear medicine supplies with ...
-
CTT to Present Data on Prostate Cancer Therapy Candidates at Upcoming Conferences
The most recent performance data on Cancer Targeted Technology’s (CTT) leading drugs, CTT1057 and CTT1403, in prostate cancer clinical and preclinical studies will be presented at several scientific and business meetings in June and one that took place in April, the company announced in a press release. The meetings featuring CTT presentations include the American Society of Clinical ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you